首页 | 本学科首页   官方微博 | 高级检索  
     


Abiraterone acetate for metastatic castration‐resistant prostate cancer after docetaxel failure: A randomized,double‐blind,placebo‐controlled phase 3 bridging study
Authors:Yinghao Sun  Qing Zou  Zhongquan Sun  Changling Li  Chuanjun Du  Zhiwen Chen  Yuxi Shan  Yiran Huang  Jie Jin  Zhang Qun Ye  Liping Xie  Guowen Lin  Yi Feng  Peter De Porre  Weiping Liu  Dingwei Ye
Affiliation:1. Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China;2. Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China;3. Department of Urology, Huadong Hospital, Fudan University, Shanghai, China;4. Department of Urology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China;5. Department of Urology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China;6. Urology Center, Southwest Hospital, Third Military Medical University, Chongqing, China;7. Department of Urinary Surgery, Second Affiliated Hospital of Soochow University, Suzhou, China;8. Department of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China;9. Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, National Urological Cancer, Beijing, China;10. Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China;11. Department of Urology, School of Medicine, First Affiliated Hospital, Zhejiang University, Hangzhou, China;12. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China;13. Janssen Research & Development, Beijing, China;14. Janssen Research & Development, Beerse, Belgium
Abstract:
Keywords:abiraterone acetate  Asian population  castration‐resistant prostate cancer  docetaxel  phase 3
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号